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TECHNICAL NOTE
Eosinophilia and pulmonary dysfunction during Cuprophan
hemodialysis
EDWARD A. MICHELSON, LEONARD COHEN, RAND E. DANKNER,
and ANTHONY KULCZYCKI, JR.
Division of Allergy and Immunology, Department of Medicine, and Howard Hughes Medical Institute Laboratory, Washington University
School of Medicine, St. Louis, Missouri
Four types of adverse events resembling immunological
reactions have been reported in patients undergoing chronic
maintenance hemodialysis: anaphylaxis [1], hypereosinophilia
[1—5], asthmatic attacks [4—6], and pulmonary leukostasis with
compromised pulmonary function [7—10]. We evaluated three
successive chronic dialysis patients who had developed acute
hypersensitivity reactions manifested by increased airway
obstruction in response to hemodialysis. Each patient also had
a non-acute reaction to dialysis, hypereosinophilia, and one
patient had urticaria. All dialyzers were ethylene oxide steril-
ized and none were reused. In these three patients the adverse
reactions abated after changing from dialyzers containing Cu-
prophan (ENKA Ag, Wuppertal, Germany) to dialyzers not
containing Cuprophan. In each patient a second exposure to
Cuprophan caused recurrence of one or more of the adverse
reactions. These case studies and our re-examination of previ-
ous observations [1—61 suggest that in some patients both acute
and chronic adverse reactions may be related to the use of
Cuprophan.
Methods and Results. Patient 1. A 50-year-old black female
with renal failure secondary to hypertension began chronic
hemodialysis in December 1975. It is uncertain which dialyzers
were used during the first 10 months of dialysis, but during her
ninth and tenth months of dialysis differential counts showed 18
and 20% eosinophils (Fig. 1). In October 1976, a one antigen-
matched cadaver kidney transplant was attempted but was
rejected and, 3 weeks later, removed. Hemodialysis was contin-
ued using coil dialyzers containing Cuprophan (ENKA Ag)
from 1976 to June 1978 (U2 dialyzers from Travenol, Deerfield,
Illinois, and ALT 100 dialyzers from Bentley Labs, Irvine,
California). Three different dialyzers containing Cuprophan
hollow fibers (ENKA Ag) were used from June to November
1978. The HD plate dialyzer (Travenol) containing Cuprophan
(ENKA Ag) membranes was used from September 1979 to July
1981. The patient's course was marked by persistence of 35 to
60% eosinophilia for 5 years and was complicated by frequent
mild dyspneic episodes. On August 18 and October 16, 1981,
the patient experienced particularly severe episodes of wheez-
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ing, nausea, flushing, and periorbital edema within 30 mm of the
initiation of dialysis with an HPF 100 dialyzer (Erika, Inc.,
Rockleigh, New Jersey) containing Cuprophan hollow fibers
(ENKA Ag) which prompted discontinuation of dialysis and
administration of diphenhydramine intramuscularly. During a
subsequent asymptomatic dialysis session using the HPF 100
dialyzer pulmonary function studies (Table 1) demonstrated
decreases in volume of air expired during first second of forced
vital capacity (FEY1), peak expiratory flow rate (PEFR), and
maximal mid-expiratory flow rate (MMEF).
The patient was switched to C-DAK 4000 dialyzers (Cordis
Dow Corp., Concord, California) on November 10, 1981 (none
of the Cordis Dow dialyzers contain Cuprophan). On December
8, the patient was dialyzed once again using the Cuprophan-
containing HPF 100 dialyzer. Fifteen minutes after initiation of
dialysis, a routine blood sample was drawn which later revealed
leukopenia (1,800 cells/mm3). Twenty-five minutes after the
onset of dialysis, the patient complained of dyspnea and her
systolic blood pressure fell 50 mm Hg. Cessation of dialysis and
injection of diphenhydramine resulted in resolution of symp-
toms. All subsequent dialysis sessions have employed C-DAK
4000 (cellulose acetate) dialyzers with reduction of eosinophilia
and symptoms, although relatively minor dyspneic episodes
still occur during dialysis. Pulmonary function studies have
demonstrated increases in FEY1 and PEFR during dialysis
sessions using C-DAK 4000 cellulose acetate dialyzers (Table
1).
A positive serum antinuclear antibody (AN A) at a dilution of
1:360 was attributed to prior use of hydralazine (anti-DNA
antibodies were negative). Multiple stool examinations revealed
neither ova nor parasites. Skin testing revealed little immediate
skin reactivity to common aeroallergens, and serum IgE levels
were consistently between 480 and 1,000 lU/mi.
Patient 2. A 44-year-old black female with endstage renal
disease secondary to hypertension began hemodialysis in
March, 1977, using UF2 dialyzers (Travenol, Deerfield, Illinois)
containing Cuprophan coils (ENKA, Ag). The patient received
a cadaveric renal transplant in October, 1978, and required
corticosteroids for episodes of graft rejection which occurred
shortly after transplantation, in December, 1978, and January,
1979.
Following multiple bouts of pneumonia and renal graft rejec-
tion, chronic hemodialysis was resumed in April, 1981, using
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Table 1. Parameters of pulmonary function before and during hemodialysis, patient Ia
Membrane
Time
mm
FVC
liters
FEYI
liters
PEFR
liters/sec
MMEF
liters/sec
Cuprophan Before 2.5 2.17 4.3 2.5
(10/22/81) 30
90
2.4 (—4%)
2.5 (0%) 1.9 (—12%)2.0 (—8%) 3.2 (—26%)3.3 (—23%) 1.9 (—24%)1.9 (—24%)
Cellulose acetate Before 2.2 1.5 1.9 1.0
(1/19/82) 90 2.2 (0%) 1.8 (+20%) 2.5 (+32%) 1.8 (+80%)
Cellulose acetate Before 2.2 1.5 1.9 0.8
(2/4/82) 90 2.2 (0%) 1.8 (+20%) 3.2 (+68%) 1.7 (+ 112%)
Abbreviations: FVC, forced vital capacity; FEV1, volume of air expired during first second of FVC; MMEF, maximal mid-expiratory flow rate;
PEFR, peak expiratory flow rate. (During hemodialysis one normally expects improvement in pulmonary function related to removal of excess
lung water [16].)
a Percentage increase of decrease from pre-dialysis value is given in parentheses.
HD 1000 dialyzers (Travenol) containing Cuprophan plate
membranes (ENKA Ag) (Fig. 2). During many dialysis ses-
sions, episodes of hypotension associated with increases in
jugular venous pressure, wheezing, coarse rales, and epigastric
pain occurred. Hypereosinophilia was noted 3 months after
initiation of dialysis with HD 1000 dialyzers, with eosinophil
counts (calculated from the differential count) rising to 7,200
cells/mm3. On July 23, 1981, dialysis was discontinued due to
marked hypotension and shortness of breath. Subsequent dialy-
ses employing C-DAK 1.3 regenerated cellulose dialyzers (Cor-
dis-Dow) have been marked by a profound decrease in eosino-
philia and an absence of episodes of hypotension and dyspnea.
Patient 3. A 20-year-old white male with endstage renal
disease secondary to hereditary medullary cystic kidney dis-
ease began chronic hemodialysis in October, 1971, using C-
DAK 1.8 (regenerated cellulose) dialyzers (Cordis-Dow) (Fig.
3). A cadaver kidney was transplanted in August, 1972, and,
despite four episodes of rejection treated with corticosteroids
and immunosuppressives, it continued to function for 5 years.
Chronic hemodialysis was reinstituted in August, 1977. During
the first week after the patient was switched to CF 1200
dialyzers (Travenol) containing Cuprophan hollow fibers
(ENKA Ag) in July 1978, he developed pruritis and urticaria
while undergoing dialysis. The urticaria did not entirely resolve
between dialysis sessions but gradually worsened. Approxi-
mately 2 hr into one dialysis session he developed a marked
worsening of the pruritis with shortness of breath and flushing.
After returning to the C-DAK 1.8 dialyzer, the urticaria re-
solved over a period of days. A second cadaver kidney was
transplanted in November of 1978, but functioned only for a
period of 3 months. In early 1979, the patient returned to
chronic hemodialysis with the C-DAK 1.8 dialyzers and experi-
enced no adverse reactions.
In June 1981 he was rechallenged in three consecutive
dialysis sessions with CF 1200 dialyzers (which contain Cupro-
phan hollow fibers) and approximately 30 to 40 mm into each
dialysis, he developed hives and pruritis involving the trunk and
upper extremities. The third dialysis session was terminated
due to development of shortness of breath and tachycardia.
Subsequently, the patient has been dialyzed only with regener-
ated cellulose dialyzers without adverse reactions.
Discussion
The first patient has had two types of adverse reactions to
hemodialysis; chronically elevated eosinophil counts over a 5-
year period and acute episodes of respiratory impairment with
angioedema. Both reactions appear to be related to the type of
dialyzer since making only one change in therapy, converting
from Cuprophan-containing dialyzers to cellulose acetate dia-
lyzers, was followed by marked reduction in the severity of
adverse respiratory reactions and a marked decrease in abso-
lute eosinophil count. The second patient had eosinophilia
during hemodialysis with Cuprophan coils during 1977 and 1978
which subsided after successful transplantation. She had acute
episodes of respiratory impairment in 1981 when dialysis was
resumed using a plate dialyzer which contained Cuprophan.
Marked eosinophilia also developed during the third month of
dialysis using the Cuprophan plate dialyzer (steroid use may
have prevented an earlier increase). After discontinuing use of
Cuprophan dialyzers, she had no further respiratory difficulties
nor marked eosinophilia. The third patient had acute respira-
tory difficulty and chronic problems with urticaria during the
initial week of dialysis (and subsequent rechallenges) with
Cuprophan hollow-fiber dialyzers. Using non-Cuprophan dia-
lyzers such symptoms did not occur. Eosinophilia (> 450
cells/mm3) was noted in his two blood samples obtained during
the period of dialysis with Cuprophan dialyzers but was not as
marked as those in the first two patients. Of 19 samples
obtained at other times, only three demonstrated eosinophilia.
Retrospective evaluation of eosinophilia is limited by the rarity
of eosinophil counts and the inaccuracy of the occasional
differential counts. However, patients 1 and 2 demonstrated
unequivocal eosinophilia during use of Cuprophan-containing
dialyzers.
It is our suggestion that dialyzers containing Cuprophan may
induce both acute anaphylaxis-like reactions and chronic reac-
tions (especially eosinophilia) in some patients. Logically, both
types of reactions should abate when use of Cuprophan is
discontinued.
A previous study, interpreted as associating eosinophilia with
dialyzer reuse and/or formaldehyde, found that four (13%) of 30
patients developed eosinophilia during hemodialysis with vari-
ous types of Cuprophan dialyzers [1]. In another study eosino-
philia was present in 19 (25%) of 77 patients undergoing
hemodialysis [2] using exclusively RSP artificial kidneys with
Cuprophan coils (Travenol). The study concluded that eosino-
philia "was somehow maintained by repetitive dialysis," but it
was not associated with reuse of membranes. In a study of IgE
levels in 62 patients undergoing hemodialysis with dialyzers
containing Cuprophan hollow fibers, it was noted that 28 (45%)
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had eosinophilia [3]. Two patients were reported with asthmatic
attacks and eosinophilia associated with hemodialysis although
the dialysis membrane was not identified in one patient [4] and
formaldehyde sterilization of the dialyzer may have been re-
sponsible for the other patient [1, 11]. In one patient (without
eosinophilia) asthmatic symptoms during hemodialysis with
Cuprophan dialyzers subsided with non-Cuprophan hemodialy-
sis [6], although significant bronchospasm ordinarily occurs
only in hemodialysis patients with eosinophilia [5].
Our patient series suggests that those maintained on chronic
hemodialysis using Cuprophan who experience unexplained
eosinophilia and/or adverse symptoms resembling immunologic
reactions might benefit by switching to non-Cuprophan dialyz-
ers. A larger prospective study to test this suggestion certainly
is warranted. Although our patients appear to have Cuprophan-
specific reactions and the majority of the previous studies
involve patients using Cuprophan dialyzers, it does not neces-
sarily follow that all hemodialysis-induced eosinophilia results
from exposure to Cuprophan. The earliest study of dialysis-
induced eosinophilia [1] reported a higher incidence of eosino-
philia in the hospital using non-Cuprophan membranes; howev-
er, it is now suspected that these patients may have resulted
from formaldehyde sterilization [11]. Another study [5] report-
ed that the incidence of persistent eosinophilia was comparable
in Cuprophan-dialyzed patients and non-Cuprophan-dialyzed
patients, although it did not indicate how long patients had been
using their respective dialyzers nor which dialyzer was used by
the five patients with bronchospasm. These two studies are not
contradictory to ours, in fact in the first study patients switched
to Cuprophan dialyzers were noted to have persistent eosino-
philia [1]. Nonetheless, these two studies and reports associat-
ing eosinophilia with peritoneal dialysis [12, 13] suggest that
substances other than Cuprophan may also be involved in
initiating eosinophilia.
A number of studies suggest that complement is activated by
exposure of blood to dialyzers containing Cuprophan and that
the complement fragments so generated lead to granulocyte and
monocyte entrapment in the pulmonary vasculature and, conse-
t.
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Fig. 3. Eosinophilslmm3 and urticaria symptoms (M) in patient 3. 1
denotes transplantation, solid bars denote Cuprophan hemodialysis,
open bars denote non-Cuprophan dialysis, and lines indicate steroid use
as in other figures.
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Fig. 1. Eosinophilslmm3 in patient 1. After November 1981 most values
were derived from absolute eosinophil counts; prior values were
calculated from differential counts. No corticosteroids were used
except during the period of transplantation, denoted as T. In this and
subsequent figures the type of dialyzer membrane is denoted by
different bars: , Cuprophan membrane; = , membrane-
type not known; = , non-Cuprophan membrane.
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Fig. 2. Eosinophilslmm3 of blood in patient 2. T denotes transplantation
and bars denote hemodialysis as in Figure 1. Lines indicate periods of
corticosteroid use.
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quently, to pulmonary dysfunction [7—10]. It appears that
Cuprophan membranes cause greater leukopenia than non-
Cuprophan membranes [14—151, Thus, one possible mechanism
to explain our observations is that Cuprophan-generated com-
plement fragments might cause basophils and mast cells to
release histamine, leukotriene B4, and other substances causing
chemotaxis and/or production of eosinophils.
Note added in proof
Eosinophilia was found in 27% of hemodialysis patients who were
studied over a period of time using Cuprophan membranes [17].
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